

## Levonorgestrel-containing intrauterine systems Comparison table

	Kyleena®	Levosert®	Benilexa®	Mirena®
<b>Choice of product</b>	<p><b>Choice of levonorgestrel (LNG) Intrauterine system (IUS) should be individualized based on age, parity, heavy periods, and for use as part of hormone replacement therapy (HRT)</b></p> <ul style="list-style-type: none"> <li>Kyleena – licensed use only for contraception for 5 years, smaller in size than other LNG-IUS with 52 mg (Mirena, Levosert, Benilexa). Kyleena provides an additional highly effective option for long-acting reversible contraception that is licensed for 5 years of use. The narrower insertion tube and smaller frame may make Kyleena an appropriate option for contraception if a woman has a narrow cervical canal or shorter uterine cavity but prefers a 5-year LNG-IUS.</li> <li>Mirena is the only IUS which is licensed for use as part of HRT for 4 years.</li> <li><b>The Faculty of Sexual and Reproductive Healthcare (FSRH) supports the use of any LNG- IUS with 52 mg of LNG as part of HRT for 5 years (off label use) <a href="https://www.fsrh.org/standards-and-guidance/documents/fsrh-ceu-statement-mirena-8-years-contraception-jan-2024/">https://www.fsrh.org/standards-and-guidance/documents/fsrh-ceu-statement-mirena-8-years-contraception-jan-2024/</a></b></li> </ul>			
<b>Levonorgestrel dose (total)</b>	19.5 mg	52 mg	52mg	52 mg
<b>Levonorgestrel dose (daily)</b> NB: dose varies over lifetime of device	7.4 - 17.5 micrograms	8.6 - 20.1 micrograms	8.6 - 20.1 micrograms	7 - 21 micrograms
<b>Licensed indications</b>	<ul style="list-style-type: none"> <li>Contraception</li> </ul>	<ul style="list-style-type: none"> <li>Contraception</li> <li>Heavy menstrual bleeding</li> </ul>	<ul style="list-style-type: none"> <li>Contraception</li> <li>Heavy menstrual bleeding</li> </ul>	<ul style="list-style-type: none"> <li>Contraception</li> <li>Idiopathic menorrhagia</li> <li>Protection from endometrial hyperplasia during estrogen replacement therapy for 4 years</li> </ul>
<b>Off label indications</b>	-	Endometrial protection as part of HRT (refer to above: use endorsed by <a href="#">FSRH guidance</a> )	Endometrial protection as part of HRT (refer to above: use endorsed by <a href="#">FSRH guidance</a> )	Endometrial protection as part of HRT for 5 years (Refer to above: use endorsed by <a href="#">FSRH guidance</a> , RCOG, BMS)

## Levonorgestrel-containing intrauterine systems

### Comparison table

	Kyleena®	Levosert®	Benilexa®	Mirena®
<b>Duration</b>	Up to five years	<p><a href="#">FSRH guidance</a> recommends use of 52 mg LNG-IUDs for 6 years for contraception if the user is &lt;45 years old at the time of insertion. Individuals who have any 52 mg LNG-IUD inserted when they are ≥45 years old can use the device for contraception until age 55 years, after which time contraception is no longer required.</p> <ul style="list-style-type: none"> <li>• Contraception: 6 years</li> <li>• Heavy menstrual bleeding: demonstrated efficacy for 3 years, remove or exchange after 6 years of use, or earlier if heavy or bothersome menstrual bleeding returns</li> <li>• HRT: 5 years (off label use, see above)</li> </ul>		<ul style="list-style-type: none"> <li>• Contraception: 8 years</li> <li>• Idiopathic menorrhagia: demonstrated efficacy for 5 years. If symptoms have not returned after 5 years, continued use may be considered. Remove or replace no later than 8 years after insertion.</li> <li>• HRT – licensed for 4 years (off label use for 5 years supported by FSRH, see above)</li> </ul>
<b>Cost</b>	£76 + VAT	£66 + VAT	£ 71 + VAT	£88 + VAT
<b>Cost per year</b>	£15.20 (5 years)	£13.20 (5 years) £11.00 (6 years)	£14.20 (5 years) £11.83 (6 years)	£17.60 (5 years) £11.00 (8 years)
<b>Size</b>	28 x 30 mm	32 x 32 mm	32 x 32 mm	32 x 32 mm
<b>Insertion tube diameter</b>	3.8 mm	4.8 mm	4.8 mm	4.4 mm
<b>Contraceptive efficacy (Pearl Index†)</b>	1 year: 0.16 5 years: 0.29	1 year: 0.15 6 years: 0.18	1 year: 0.15 6 years: 0.18	1 year: 0.21 8 years: 0.00
<b>Safety information</b>	<p>Levonorgestrel-releasing IUS should always be prescribed by brand name because products have different indications, durations of use, and introducers (See <a href="#">Drug Safety Update</a>, January 2016)</p> <p>Before inserting an IUS or IUD, inform women of the risk of perforation and risk factors for perforation (See <a href="#">Drug Safety Update</a>, June 2015)</p>			
<b>Insertion</b>	One handed Evolserter™ Cannot be reloaded	Two-handed inserter Cannot be reloaded	One handed inserter Can be reloaded	One handed Evolserter™ Cannot be reloaded



## Levonorgestrel-containing intrauterine systems Comparison table

	Kyleena®	Levosert®	Benilexa®	Mirena®
<b>Silver ring for improved visibility on ultrasound?</b>	Yes	No	No	No
<b>Visible on X-ray?</b>	Yes	Yes	Yes	Yes
<b>Other information</b>	Placement considered by clinicians to be easier than for Mirena (94% vs. 86% rated as “easy”, p<0.001). Women more likely to report no pain or mild pain during placement than for Mirena (72% vs. 58%, p<0.001)	Minimum uterine depth: 5.5 cm.		

† The Pearl Index is a measure of contraceptive efficacy essentially equivalent to the annual pregnancy risk if 100 women were to use a specific method of contraception.

# Levonorgestrel-containing intrauterine systems

## Comparison table

### References and additional information

- FSRH Clinical Guideline: Intrauterine Contraception. March 23, amended in July 2023. <https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/>
- Levosert 20 micrograms/24 hours Intrauterine Delivery System - Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/1789>
- Benilexa One Handed 20 micrograms/24 hours Intrauterine Delivery System - Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/13055>
- Kyleena 19.5 mg intrauterine delivery system - Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/769>
- Mirena 20 micrograms/24 hours intrauterine delivery system - Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/1132>
- NICE Guidelines on Heavy Menstrual Bleeding 2018, updated in May 21 <https://www.nice.org.uk/guidance/ng88/chapter/Recommendations#management-of-hmb>
- FSRH CEU Statement: Mirena 8 years contraception (Jan 2024). <https://www.fsrh.org/documents/fsrh-ceu-statement-mirena-8-years-contraception-jan-2024>
- Levonorgestrel-releasing intrauterine systems: prescribe by brand name - GOV.UK. <https://www.gov.uk/drug-safety-update/levonorgestrel-releasing-intrauterine-systems-prescribe-by-brand-name>
- Intrauterine contraception: uterine perforation—updated information on risk factors - GOV.UK. <https://www.gov.uk/drug-safety-update/intrauterine-contraception-uterine-perforation-updated-information-on-risk-factors>